Overview

Acalabrutinib in CNSL

Status:
Not yet recruiting

Trial end date:
2025-01-31

Target enrollment:

Participant gender:

Summary

This research study is a Phase 1/2 clinical trial testing the safety, tolerance and efficacy of the drug Acalabrutinib for people with recurrent or refractory central nervous system lymphoma (CNSL).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Treatments:

Acalabrutinib